Related Experiment Video
Updated: Jul 21, 2026
07:04
Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation
Published on: September 16, 2018
NIH conference. Immunomodulators in clinical medicine
Annals of Internal Medicine
|March 1, 1987
Summary
Immunomodulators offer promising cancer treatments, but their complexity challenges clinical use. Research explores targeted therapies like interleukin-2 and interferons for improved specificity and efficacy in various diseases.
Area of Science:
- Immunology
- Oncology
- Virology
Background:
- The complexity of the immune system hinders specific immunomodulator therapies.
- Lymphokine-activated killer cells with interleukin-2 show efficacy in advanced cancers.
- Interferons and monoclonal antibodies are emerging as key therapeutic agents.
Purpose of the Study:
- To review the current landscape and challenges of immunomodulator therapies.
- To highlight the therapeutic potential of specific immunomodulators in various diseases.
- To discuss the role of immunomodulators in acquired immunodeficiency syndrome treatment.
Main Methods:
- Review of existing literature on immunomodulator applications.
- Analysis of clinical data for interleukin-2 and interferon therapies.
- Examination of monoclonal antibody roles in oncology and immune diseases.
Main Results:
- Interleukin-2 demonstrates effectiveness in metastatic renal cell carcinoma.
- Alpha-interferon exhibits antitumor effects in hairy cell leukemia and antiviral activity.
- Monoclonal antibodies are increasingly utilized in diagnostics and therapeutics.
Conclusions:
- Despite challenges, immunomodulators show significant therapeutic promise.
- Targeted immunotherapies are advancing cancer and immune-related disease treatment.
- Ongoing research continues to expand the clinical applications of immunomodulators.
Related Concept Videos
01:17Drugs Used in Lower Respiratory Disorders: Overview
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:25Immunodeficiency Diseases
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...
There are three main causes of immunodeficiency disorders...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...